Binimetinib

(Mektovi)

Binimetinib

Drug updated on 11/16/2023

Dosage FormTablet (oral; 15 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • In combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Mektovi (binimetinib) Prescribing Information.2023Array BioPharma Inc., Boulder, CO

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV).2021ACTAS Dermo-Sifiliogr√°ficas
Systemic therapy for melanoma: ASCO guideline.2020American Society of Clinical Oncology